Anthropic Targets BioTech Growth With $400 Million Coefficient Bio Buy

Anthropic has acquired Coefficient Bio, an artificial intelligence (AI) BioTech startup founded last fall, for about $400 million, The Information reported Thursday (April 2), citing an unnamed source.

The Coefficient Bio team, which includes fewer than 10 employees and was developing a platform that uses AI for planning drug research and development, managing clinical regulatory strategy and identifying new drug opportunities, will join Anthropic’s healthcare life sciences group, according to the report.

Neither Anthropic nor Coefficient Bio immediately replied to PYMNTS’ request for comment.

PYMNTS reported in January that Anthropic is pushing deeper into life sciences. Through Claude for Life Sciences, the company is positioning its models as research partners embedded in scientific environments and connected to platforms like PubMed, Benchling and ClinicalTrials.gov. The focus is on biomedical research tasks such as literature synthesis, hypothesis generation, clinical trial planning and regulatory documentation.

When Anthropic announced in February that it raised $30 billion in a Series G funding round that valued the company at $380 billion, it attributed the investors’ interest in part to its strength in enterprise AI and coding. Anthropic said it would use the new funding to support that strength with continued frontier research, product development and infrastructure expansions.

“The same capabilities that make [Anthropic’s AI model] Claude exceptional for coding are also unlocking other new categories of work: financial and data analysis, sales, cybersecurity, scientific discovery, and beyond,” the company said in a Feb. 12 press release.

Later in February, PYMNTS reported that Anthropic is pushing more “out-of-the-box” AI agents for functions like finance and research.

It was reported in February that pharmaceutical companies are reshaping their operating models around AI. Drugmakers are embedding machine learning into trial execution and compliance infrastructure, targeting the costliest and most failure-prone bottlenecks in how therapies are tested, reviewed and brought to market.

The PYMNTS Intelligence and AI-ID collaboration “Generative AI Can Elevate Health and Revolutionize Healthcare” found that stakeholders in healthcare, technology and investment sectors recognize the potential of AI’s transformative impact on health and medicine. Gen AI innovations are expanding researchers’ capabilities and accelerating drug discovery and diagnostics, the report found.

For all PYMNTS AI coverage, subscribe to the daily AI Newsletter.